Remix Therapeutics
Clinical-stage biotechnology company developing small molecules that modulate RNA processing to treat cancer and other serious diseases. Their REMaster platform targets RNA splicing and processing to create novel therapeutics.
Notes
Remix Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapeutics by modulating RNA processing with small molecules. Founded in 2018, the company is headquartered in Cambridge, Massachusetts.
The company's proprietary REMaster platform enables the discovery and development of small molecules that modulate RNA processing, including splicing, to treat a variety of diseases. Their lead program REM-422 is being developed for oncology indications.
Remix has raised significant funding from top-tier investors to advance its pipeline of RNA-modulating therapeutics.
Team
- Rohan Palekar - Chief Executive Officer
- Jens Eckstein, Ph.D. - Co-founder
- Benjamin Blencowe, Ph.D. - Co-founder, Scientific Advisory Board
- Adrian Krainer, Ph.D. - Co-founder, Scientific Advisory Board
Additional Research Findings
- Investor: Alexandria Venture Investments, Third Rock Ventures, and others
- Focus on RNA processing modulation using small molecules
- REMaster platform for drug discovery
- Lead program: REM-422 (oncology)
- Clinical-stage company with active trials
- Cambridge, MA headquarters
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Alexandria Venture Investments | Pasadena, USA | cvc | seedseries-a+3 | 6 |